JO
CAPR icon

John Overdeck’s Capricor Therapeutics CAPR Stock Holding History

John Overdeck’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-30,932
Closed -$940K – 5080
2026
Q1 		$940K Sell
30,932
-23,841
-44% -$635K ﹤0.01% 3306
2025
Q4 		$1.58M Sell
54,773
-301,023
-85% -$3.93M ﹤0.01% 2612
2025
Q3 		$2.57M Buy
355,796
+199,959
+128% +$1.47M ﹤0.01% 1960
2025
Q2 		$1.55M Buy
155,837
+30,882
+25% +$326K ﹤0.01% 1998
2025
Q1 		$1.19M Buy
124,955
+5,908
+5% +$82K ﹤0.01% 2080
2024
Q4 		$1.64M Buy
119,047
+82,254
+224% +$1.44M ﹤0.01% 1852
2024
Q3 		$560K Buy
36,793
+12,882
+54% +$63.7K ﹤0.01% 2416
2024
Q2 		$114K Sell
23,911
-89
-0.4% -$496 ﹤0.01% 2806
2024
Q1 		$163K Buy
24,000
+4,300
+22% +$20.8K ﹤0.01% 2760
2023
Q4 		$96.3K Buy
+19,700
New +$64.1K ﹤0.01% 2942
2020
Q3 		– Sell
-43,407
Closed -$200K – 3114
2020
Q2 		$200K Buy
+43,407
New +$189K ﹤0.01% 2638
2020
Q1 		– Sell
-40,680
Closed -$52K – 3152
2019
Q4 		$52K Buy
+40,680
New +$83.9K ﹤0.01% 3568

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

John Overdeck's CAPR Position: Q2 2026 in Review

John Overdeck sold out of Capricor Therapeutics (CAPR) in Q2 2026, closing a stake of 30,932 shares — an estimated $940K sold.

John Overdeck first reported a position in CAPR in Q4 2019 and held it in 12 quarters. The position peaked at $2.57M in Q3 2025. 169 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • John Overdeck reported no remaining Capricor Therapeutics position as of Q2 2026 after selling out during the quarter.
  • John Overdeck sold 30,932 Capricor Therapeutics shares in Q2 2026, an estimated $940K.
  • John Overdeck first reported a position in Capricor Therapeutics in Q4 2019 and held it in 12 quarters.
  • John Overdeck's Capricor Therapeutics position peaked at $2.57M in Q3 2025.
  • 169 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.